1. Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy
- Author
-
Daniela Rehakova, Irena Koutná, and Tereza Souralová
- Subjects
Pluripotent Stem Cells ,Induced Pluripotent Stem Cells ,Cell- and Tissue-Based Therapy ,Review ,clinical ,Catalysis ,hiPSC ,Inorganic Chemistry ,Cell therapy ,lcsh:Chemistry ,03 medical and health sciences ,Mycoplasma ,0302 clinical medicine ,Characterization methods ,Humans ,Medicine ,characterization ,human pluripotent stem cells ,Physical and Theoretical Chemistry ,Human Induced Pluripotent Stem Cells ,Induced pluripotent stem cell ,Molecular Biology ,lcsh:QH301-705.5 ,Spectroscopy ,030304 developmental biology ,hPSCs ,0303 health sciences ,Bacteria ,business.industry ,Organic Chemistry ,Clinical grade ,General Medicine ,human embryonic stem cells ,Embryonic stem cell ,3. Good health ,Computer Science Applications ,Endotoxins ,human induced pluripotent stem cells ,cGMP ,Clinical trial ,lcsh:Biology (General) ,lcsh:QD1-999 ,hESC ,Viruses ,Cancer research ,cell therapy ,business ,030217 neurology & neurosurgery - Abstract
Human pluripotent stem cells have the potential to change the way in which human diseases are cured. Clinical-grade human embryonic stem cells and human induced pluripotent stem cells have to be created according to current good manufacturing practices and regulations. Quality and safety must be of the highest importance when humans’ lives are at stake. With the rising number of clinical trials, there is a need for a consensus on hPSCs characterization. Here, we summarize mandatory and ′for information only′ characterization methods with release criteria for the establishment of clinical-grade hPSC lines.
- Published
- 2020